Elicio Therapeutics (ELTX) Preferred Stock Liabilities (2021 - 2023)

Elicio Therapeutics (ELTX) has reported Preferred Stock Liabilities for 3 consecutive years, with $111.1 million the latest figure, recorded in Q1 2023.

• For the quarter ending Q1 2023, Preferred Stock Liabilities rose 57.67% year-over-year to $111.1 million; the trailing twelve-month figure through Mar 2023 stood at $111.1 million (up 57.67% YoY), and the FY2022 full-year result was $111.1 million, up 57.67% from the prior year.
• Preferred Stock Liabilities steadied at $111.1 million in Q1 2023 per ELTX's latest filing, from $111.1 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $111.1 million in Q4 2022 and bottomed at $70.4 million in Q4 2021.
• Historically, Preferred Stock Liabilities has averaged $85.8 million across 3 years, with a median of $76.0 million in 2022.
• The widest YoY moves for Preferred Stock Liabilities: up 57.67% in 2022, down 57.67% in 2022.
• Over 3 years, Preferred Stock Liabilities stood at $70.4 million in 2021, then surged by 57.67% to $111.1 million in 2022, then changed by 0.0% to $111.1 million in 2023.
• According to Business Quant data, Preferred Stock Liabilities over the past three periods registered $111.1 million, $111.1 million, and $80.4 million for Q1 2023, Q4 2022, and Q3 2022 respectively.